Bishal Gyawali: 15 most FAQs about surrogate endpoints in oncology

Bishal Gyawali shared a post by Oncology News Central on X, adding:

“My new piece in Oncology News Central where I discuss 15 most frequently asked questions about surrogate endpoints in oncology based on our recent eClinicalMedicine – The Lancet Discovery Science paper.”

Quoting Oncology News Central:

“Surrogate endpoints in oncology trials remain controversial. Our latest article answers 15 common questions, addressing pitfalls and the way forward. Learn why OS and QoL should be the gold standards.”

Surrogate Endpoints: The 15 Most Common Misunderstandings in Oncology

Authors: Bishal Gyawali.

Bishal Gyawali, MD, PhD, is a medical oncologist from Nepal. Currently an Associate Professor at Queen’s University, Kingston, Canada, and affiliated with Brigham and Women’s Hospital, Boston, USA, he is involved in global oncology initiatives. Dr. Gyawali serves on several committees, including the WHO Essential Medicines List Cancer Medicines Working Group and ASCO’s Health Equity and Outcomes Committee, contributing significantly to cancer policy and evidence-based oncology.